The role of survivin for radiation therapy: Prognostic and predictive factor and therapeutic target

Strahlentherapie und Onkologie

Volumn 183, Issue 11, 2007, Pages 593-599

  Capalbo, Gianni ^a   Rödel, Claus ^a   Stauber, Roland H ^b   Knauer, Shirley K ^b   Bache, Matthias ^c   Kappler, Matthias ^c   Rödel, Franz ^a  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^c MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Apoptosis; Radiooncology; Survivin; Therapeutic target

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; RIBOZYME; SMALL INTERFERING RNA; SURVIVIN;

APOPTOSIS; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CELL DIVISION; CELL SURVIVAL; CLINICAL RESEARCH; CLINICAL TRIAL; DRUG MECHANISM; HUMAN; IONIZING RADIATION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; RADIOSENSITIVITY; REVIEW; TREATMENT RESPONSE; TUMOR; TUMOR GROWTH; TUMOR RESISTANCE;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; OLIGONUCLEOTIDES, ANTISENSE; PROGNOSIS; RADIATION ONCOLOGY; RADIATION TOLERANCE; RADIOTHERAPY DOSAGE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; TUMOR CELLS, CULTURED;

EID: 36248971578     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00066-007-1800-4     Document Type: Review

References (65)

1. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer 2003;3:46-54.
2. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997;3:917-21.
3. Asanuma K, Moriai R, Yajima T, et al. Survivin as a radioresistance factor in pancreatic cancer. Jpn J Cancer Res 2000;91:1204-9.
4. Bache M, Holzapfel D, Kappler M, et al. Survivin protein expression and hypoxia in advanced cervical carcinoma of patients treated by radiotherapy. Gynecol Oncol 2007;104:139-44.
5. Badran A, Yoshida A, Ishikawa K, et al. Identification of a novel splice variant of the human anti-apoptopsis gene survivin. Biochem Biophys Res Commun 2004;314:902-7.
6. Baierlein SA, Distel L, Sieber R, et al. Combined effect of tumor necrosis factor-alpha and ionizing radiation on the induction of apoptosis in 5637 bladder carcinoma cells. Strahlenther Onkol 2006;182:467-72.
7. Banks DP, Plescia J, Altieri DC, et al. Survivin does not inhibit caspase-3 activity. Blood 2000;96:4002-3.
8. Burdak-Rothkamm S, Rube CE, Nguyen TP, et al. Radiosensitivity of Tumor Cell Lines after Pretreatment with the EGFR Tyrosine Kinase Inhibitor ZD1839 (Iressa®). Strahlenther Onkol 2005;181:197-204.
9. Caldas H, Honsey LE , Altura RA. Survivin 2alpha: a novel Survivin splice variant expressed in human malignancies. Mol Cancer 2005;4:11.
10. Cao C, Mu Y, Hallahan DE, et al. XIAP and survivin as therapeutic targets for radiation sensitization in preclinical models of lung cancer. Oncogene 2004;23:7047-52.
11. Chakravarti A, Zhai GG, Zhang M, et al. Survivin enhances radiation resistance in primary human glioblastoma cells via caspase-independent mechanisms. Oncogene 2004;23:7494-506.
12. Chen J, Wu W, Tahir SK, et al. Down-regulation of survivin by antisense oligonucleotides increases apoptosis, inhibits cytokinesis and anchorage-independent growth. Neoplasia 2000;2:235-41.
13. Colnaghi R, Connell CM, Barrett RM, et al. Separating the anti-apoptotic and mitotic roles of survivin. J Biol Chem 2006;281:33450-06.
14. Dohi T, Okada K, Xia F, et al. An IAP-IAP complex inhibits apoptosis. J Biol Chem 2004;279:34087-90.
15. Fortugno P, Wall NR, Giodini A, et al. Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function. J Cell Sci 2002;115:575-85.
16. Fortugno P, Beltrami E, Plescia J, et al. Regulation of survivin function by Hsp90. Proc Natl Acad Sci U S A 2003;100:13791-6.
17. Freier K, Pungs S, Sticht C, et al. High survivin expression is associated with favorable outcome in advanced primary oral squamous cell carcinoma after radiation therapy. Int J Cancer 2007;120:942-6.
18. Fukuda S, Pelus LM. Regulation of the inhibitor-of-apoptosis family member survivin in normal cord blood and bone marrow CD34(+) cells by hematopoietic growth factors: implication of survivin expression in normal hematopoiesis. Blood 2001;98:2091-100.
19. Fukuda S , Pelus LM. Survivin, a cancer target with an emerging role in normal adult tissues. Mol Cancer Ther 2006;5:1087-98.
20. Grumann T, Arab A, Bode C, et al. Reoxygenation of human coronary smooth muscle cells suppresses HIF-1alpha gene expression and augments radiation-induced growth delay and apoptosis. Strahlenther Onkol 2006;182:16-21.
21. Hanahan D , Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
22. Hunter AM, Lacasse EC , Korneluk RG. The inhibitors of apoptosis (IAPs) as cancer targets. Apoptosis 2007;12:1543-68.
23. Iizuka D, Inanami O, Kashiwakura I, et al. Purvalanol A enhances cell killing by inhibiting up-regulation of CDC2 kinase activity in tumor cells irradiated with high doses of X rays. Radiat Res 2007;167:563-71.
24. Kami K, Doi R, Koizumi M, et al. Downregulation of survivin by siRNA diminishes radioresistance of pancreatic cancer cells. Surgery 2005;138:299-305.
25. Kappler M, Bache M, Bartel F, et al. Knockdown of survivin expression by small interfering RNA reduces the clonogenic survival of human sarcoma cell lines independently of p53. Cancer Gene Ther 2004;11:186-93.
26. Kappler M, Taubert H, Bartel F, et al. Radiosensitization, after a combined treatment of survivin siRNA and irradiation, is correlated with the activation of caspases 3 and 7 in a wt-p53 sarcoma cell line, but not in a mt-p53 sarcoma cell line. Oncol Rep 2005;13:167-72.
27. Kappler M, Rot S, Taubert H, et al. Knock down of survivin, survivin-2B or survivin-delta 3 in combination with irradiation affects clonogenic survival in a soft tissue sarcoma cell line under normoxic and hypoxic conditions. Cancer Gene Ther 2007, in press.
28. Kim KW, Mutter RW, Willey CD, et al. Inhibition of survivin and aurora B kinase sensitizes mesothelioma cells by enhancing mitotic arrests. Int J Radiat Oncol Biol Phys 2007;67:1519-25.
29. Kim PJ, Plescia J, Clevers H, et al. Survivin and molecular pathogenesis of colorectal cancer. Lancet 2003;362:205-9.
30. Knauer SK, Bier C, Schlag P, et al. The survivin isoform survivin-3B is cytoprotective and can function as a chromosomal passenger complex protein. Cell Cycle 2007;6:1502-9.
31. Knauer SK, Kramer OH, Knosel T, et al. Nuclear export is essential for the tumor-promoting activity of survivin. Faseb J 2007;21:207-16.
32. Knauer SK, Mann W, Stauber RH. Survivin's dual role: an export's view. Cell Cycle 2007;6:518-21.
33. Knutsen A, Adell G , Sun XF. Survivin expression is an independent prognostic factor in rectal cancer patients with and without preoperative radiotherapy. Int J Radiat Oncol Biol Phys 2004;60:149-55.
34. Kobayashi K, Hatano M, Otaki M, et al. Expression of a murine homologue of the inhibitor of apoptosis protein is related to cell proliferation. Proc Natl Acad Sci U S A 1999;96:1457-62.
35. LaCasse EC, Baird S, Korneluk RG, et al. The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene 1998;17:3247-59.
36. Lens SM, Vader G , Medema RH. The case for Survivin as mitotic regulator. Curr Opin Cell Biol 2006;18:616-22.
37. Li F, Ackermann EJ, Bennett CF, et al. Pleiotropic cell-division defects and apoptosis induced by interference with survivin function. Nat Cell Biol 1999;1:461-66.
38. Li F , Altieri DC. Transcriptional analysis of human survivin gene expression. Biochem J 1999;344:305-11.
39. Li F , Altieri DC. The cancer antiapoptosis mouse survivin gene: characterization of locus and transcriptional requirements of basal and cell cycledependent expression. Cancer Res 1999;59:3143-51.
40. Lu B, Mu Y, Cao C, et al. Survivin as a therapeutic target for radiation sensitization in lung cancer. Cancer Res 2004;64:2840-45.
41. Mahotka C, Wenzel M, Springer E, et al. Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res 1999;59:6097-102.
42. Marusawa H, Matsuzawa S, Welsh K, et al. HBXIP functions as a cofactor of survivin in apoptosis suppression. Embo J 2003;22:2729-40.
43. Mesri M, Morales-Ruiz M, Ackermann EJ, et al. Suppression of vascular endothelial growth factor-mediated endothelial cell protection by survivin targeting. Am J Pathol 2001;158:1757-65.
44. Nieder C, Andratschke N, Price RE, et al. Acceleration of normal-tissue damage expression by early stimulation of cell proliferation in rat spinal cord. Strahlenther Onkol 2006;182:680-84.
45. O'Connor DS, Grossman D, Plescia J, et al. Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc Natl Acad Sci USA 2000;97:13103-07.
46. Pennati M, Binda M, Colella G, et al. Radiosensitization of human melanoma cells by ribozyme-mediated inhibition of survivin expression. J Invest Dermatol 2003;120:648-54.
47. Pennati M, Folini M, Zaffaroni N. Targeting survivin in cancer therapy: fulfilled promises and open questions. Carcinogenesis 2007;28:1133-39.
48. Rödel C, Haas J, Groth A, et al. Spontaneous and radiation-induced apoptosis in colorectal carcinoma cells with different intrinsic radiosensitivities: survivin as a radioresistance factor. Int J Radiat Oncol Biol Phys 2003;55:1341-7.
49. Rödel F, Hoffmann J, Grabenbauer GG, et al. High survivin expression is associated with reduced apoptosis in rectal cancer and may predict disease-free survival after preoperative radiochemotherapy and surgical resection. Strahlenther Onkol 2002;178:426-35.
50. Rödel F, Hoffmann J, Distel L, et al. Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer. Cancer Res 2005;65:4881-7.
51. Rödel F, Müller B, Sieber R, et al. Der Apotoseinhibitor Survivin beeinflusst als Radioresistenzfaktor auch den Zellzyklus und DNA-Reparatur-Mechanismen. Strahlenther Onkol 2005;181 (Sondernr 1):77.
52. Rödel F, Müller B, Sieber R, et al. Steigerung der Apoptoserate und Strahlensensibilisierung kolorektaler Karzinomzellen durch eine Antisense-Oligonukleotid (Lilly LY2181308) vermittele Inhibition von Survivin. Strahlenther Onkol 2006;182 (Sondernr 1):90.
53. Rödel F, Knauer S, Mann W, et al. Ein nukleärer Export ist essentiell für die antiapoptotische Wirksamkeit von Survivin. Strahlenther Onkol 2007;183(Sondernr 1):60.
54. Schimmer AD. Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice. Cancer Res 2004;64:7183-90.
55. Shi W, Bastianutto C, Li A, et al. Multiple dysregulated pathways in nasopharyngeal carcinoma revealed by gene expression profiling. Int J Cancer 2006;119:2467-75.
56. Shin S, Sung BJ, Cho YS, et al. An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry 2001;40:1117-23.
57. Song Z, Yao X , Wu M. Direct interaction between survivin and Smac/DIABLO is essential for the anti-apoptotic activity of survivin during taxol-induced apoptosis. J Biol Chem 2003;278:23130-40.
58. Stauber RH, Mann W, Knauer SK. Nuclear and cytoplasmic survivin: molecular mechanism, prognostic, and therapeutic potential. Cancer Res 2007;67:5999-6002.
59. Suzuki Y, Oka K, Yoshida D, et al. Correlation between survivin expression and locoregional control in cervical squamous cell carcinomas treated with radiation therapy. Gynecol Oncol 2007;104:642-46.
60. Vagnarelli P, Earnshaw WC. Chromosomal passengers: the four-dimensional regulation of mitotic events. Chromosoma 2004;113:211-22.
61. Warnecke-Eberz U, Hokita S, Xi H, et al. Overexpression of survivin mRNA is associated with a favorable prognosis following neoadjuvant radiochemotherapy in esophageal cancer. Oncol Rep 2005;13:1241-6.
62. Weiss C, Rödel F, Wolf I, et al. Combined-modality treatment and organ preservation in bladder cancer. Do molecular markers predict outcome? Strahlenther Onkol 2005;181:213-22.
63. Xia F, Altieri DC. Mitosis-independent survivin gene expression in vivo and regulation by p53. Cancer Res 2006;66:3392-5.
64. Yang L, Cao Z, Li F, et al. Tumor-specific gene expression using the survivin promoter is further increased by hypoxia. Gene Ther 2004;11:1215-23.
65. Yip KW, Shi W, Pintilie M, et al. Prognostic significance of the Epstein-Barr virus, p53, Bcl-2, and survivin in nasopharyngeal cancer. Clin Cancer Res 2006;12:5726-32.